文献速递细菌感染、耐药与抗菌药物

BioFire FilmArray 血培养鉴定(BCID)Panel 分子快速诊断检测与传统方法鉴定大肠埃希菌血流感染的成本效果数学建模

Mathematical model of the cost-effectiveness of the BioFire FilmArray Blood Culture Identification (BCID) Panel molecular rapid diagnostic test compared with conventional methods for identification of Escherichia coli bloodstream infections.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

本研究构建决策分析模型,从公共医疗付费方角度比较 BCID 与传统方法在住院大肠埃希菌血流感染鉴定与药敏检测中的成本效果。蒙特卡洛概率分析显示 BCID 节省成本(27070.83 加元 vs 35649.81 加元)并改善 QALYs(8.65 vs 7.10);在支付意愿上限 100000 加元时,BCID 具有成本效果的概率为 72.6%-83.8%。作者结论为 BCID 用于诊断大肠埃希菌血流感染较传统检测节省成本,成本节省最受住院时长与每日住院费用影响。

要点

  • BCID 较传统方法节省成本:27070.83 加元 vs 35649.81 加元
  • BCID 改善 QALYs:8.65 vs 7.10
  • 支付意愿上限 100000 加元时 BCID 具成本效果概率 72.6%-83.8%

核心结论

  • BCID 用于诊断大肠埃希菌血流感染较传统检测节省成本。
  • 成本节省最受住院时长与每日住院费用影响。

研究设计与样本

  • 构建决策分析模型,从公共医疗付费方角度比较 BCID 与传统方法对住院大肠埃希菌血流感染患者的鉴定与药敏检测。
  • 模型输入来自已发表文献,成本均以 2019 年加拿大元计。
  • 开展蒙特卡洛概率敏感性分析与单因素敏感性分析以评估模型稳健性。

主要发现

  • 蒙特卡洛概率分析显示 BCID 节省成本(27070.83 加元 vs 35649.81 加元)并改善 QALYs(8.65 vs 7.10),结果支持 BCID。
  • 在支付意愿上限 100000 加元时,BCID 具有成本效果的概率为 72.6%-83.8%。
  • 单因素敏感性分析显示住院时长与每日住院费用对成本与 QALYs 影响最大。

关键数值与推荐

  • BCID 组每患者入院成本 27070.83 加元 vs 传统方法组 35649.81 加元。
  • BCID 组 QALYs 8.65 vs 传统方法组 7.10。
  • 支付意愿上限 100000 加元时 BCID 具成本效果的概率为 72.6%-83.8%。

临床怎么用

  • 作者结论认为 BCID 用于诊断大肠埃希菌血流感染较传统检测节省成本。
  • 成本节省最受住院时长与每日住院费用影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gram-negative pathogens, such as Escherichia coli, are common causes of bloodstream infections (BSIs) and increasingly demonstrate antimicrobial resistance. Molecular rapid diagnostic tests (mRDTs) offer faster pathogen identification and susceptibility results, but higher costs compared with conventional methods. We determined the cost-effectiveness of the BioFire FilmArray Blood Culture Identification (BCID) Panel, as a type of mRDT, compared with conventional methods in the identification of E. coli BSIs. METHODS: We constructed a decision analytic model comparing BCID with conventional methods in the identification and susceptibility testing of hospitalized patients with E. coli BSIs from the perspective of the public healthcare payer. Model inputs were obtained from published literature. Cost-effectiveness was calculated by determining the per-patient admission cost, the QALYs garnered and the incremental cost-effectiveness ratios (ICERs) where applicable. Monte Carlo probabilistic sensitivity analyses and one-way sensitivity analyses were conducted to assess the robustness of the model. All costs reflect 2019 Canadian dollars. RESULTS: The Monte Carlo probabilistic analyses resulted in cost savings ($27 070.83 versus $35 649.81) and improved QALYs (8.65 versus 7.10) in favour of BCID. At a willingness to pay up to $100 000, BCID had a 72.6%-83.8% chance of being cost-effective. One-way sensitivity analyses revealed length of stay and cost per day of hospitalization to have the most substantial impact on costs and QALYs. CONCLUSIONS: BCID was found to be cost-saving when used to diagnose E. coli BSI compared with conventional testing. Cost savings were most influenced by length of stay and cost per day of hospitalization.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Mponponsuo K, Leal J, Spackman E, et al. Mathematical model of the cost-effectiveness of the BioFire FilmArray Blood Culture Identification (BCID) Panel molecular rapid diagnostic test compared with conventional methods for identification of Escherichia coli bloodstream infections. J Antimicrob Chemother. 2022. PMID: 34734238. doi:10.1093/jac/dkab398

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。